Medline Inc. faced a significant stock price drop after the FDA issued a warning for serious violations in its pharmaceutical manufacturing practices, including failure to investigate discrepancies and microbial contamination. The stock fell over 7% following the FDA letter and dropped further by 12% after disappointing Q2 results and lowered full-year earnings guidance. Investors who suffered losses may have legal rights under federal securities laws, with a law firm investigating potential claims.
On September 3, 2026, several US-listed spot XRP ETFs surged by up to 17%, roughly double the 7-8% gain of the XRP token itself. This created a significant pricing imbalance where some ETFs traded at a premium to their net asset value (NAV), driven b...
Lufax Holding Ltd. presents an investment opportunity based on deep value and potential capital return events, rather than a business turnaround. Despite regulatory pressures and compliance issues impacting its stock, the company's strong balance she...
Dash surged 33.6% to $66.55, leading crypto gainers despite Bitcoin falling 1.2% to $79,716. The broader market showed mixed results with altcoins like NEAR also posting gains, while Bitcoin dominance remained high at 59.1%. The Fear and Greed Index ...
Ripple has signed a multi-year sponsorship with University of Florida Athletics, starting the 2026 football season, featuring XRP branding at Ben Hill Griffin Stadium, known as "The Swamp." The deal, estimated at up to $5 million annually, includes f...
DASH surged 17.5% to $56.85, its highest since May, driven by a rally in privacy coins and Grayscale's spot Zcash ETF surpassing $400M in assets. The token gained about 85% from mid-August lows near $30, supported by bullish technical signals like a ...
